The KMT2A-MENIN complex is a therapeutic vulnerability in SETBP1-mutant leukemia
SET binding protein 1 ( SETBP1 ) is recurrently mutated in high-risk myeloid malignancies, including myelodysplastic/myeloproliferative overlap disorders (MDS/MPNs) and is associated with poor clinical outcomes. Although SETBP1 mutations promote self-renewal and HOX-driven transcription in murine and cell line models, the epigenetic dependencies sustaining these programs in human hematopoietic stem and progenitor cells (HSPCs) remain poorly defined. Here, we identify the KMT2A-MENIN complex as a targetable dependency in SETBP1 -mutant leukemia. Expression of SETBP1 D886N enhanced growth and serial replating of human HSPCs and established a transcriptionally permissive chromatin state, with increased H3K4me3, H3K27ac and KMT2A occupancy at SETBP1 -regulated loci. Integrated transcriptional and chromatin profiling defined a 94-gene SETBP1 regulome containing HOXA9 , MEIS1 , MECOM , and MYB and was enriched for transcriptional programs associated with KMT2A -rearranged, NUP98-HOXA9 , and NPM1 -mutant leukemias. CRISPR-Cas9 disruption revealed a functional requirement for KMT2A, but not for KMT2B or DOT1L in SETBP1 D886N HSPCs. Strikingly, deletion of the KMT2A cofactor MEN1 phenocopied KMT2A loss. Disruption of either KMT2A or MEN1 suppressed SETBP1 -driven proliferation and leukemogenic transcriptional programs, including leukemia stem cell-associated signatures. We next exploited this dependency pharmacologically. A KMT2A-MENIN inhibitor suppressed canonical SETBP1 target genes and abolished mutant SETBP1 -driven serial replating while promoting hematopoietic differentiation and reducing H3K4me3 at leukemogenic loci, despite modest effects on short-term proliferation. Most importantly, three clinically relevant KMT2A-MENIN interaction inhibitors impaired clonogenic growth across primary SETBP1 -mutant leukemia patient samples, while inducing myeloid differentiation and suppressing SETBP1 target gene expression. Together, these findings identify the KMT2A-MENIN complex as a key therapeutic vulnerability in SETBP1 -mutant leukemia. The consistent activity of multiple MENIN inhibitors across a variety of SETBP1 -mutant patient samples and cell models validates the KMT2A-MENIN interaction as an actionable vulnerability and provides a strong rationale for expanding MENIN-directed therapies to SETBP1 -mutant myeloid malignancies.
Authors
- Samantha Tauchmann (ORCID: https://orcid.org/0000-0003-0336-9770)
- Theodore P. Braun (ORCID: https://orcid.org/0000-0002-6248-2143)
- Hanqian L. Carlson (ORCID: https://orcid.org/0009-0009-8446-0509)
- Julia E. Maxson (ORCID: https://orcid.org/0000-0002-3871-7221)
- Amara Pang (ORCID: https://orcid.org/0000-0002-2347-6656)
- TuDung T. Nguyen (ORCID: https://orcid.org/0000-0002-8988-4003)
Institutions
- Oregon Health & Science University (US)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-11-19
- DOI
- https://doi.org/10.64898/2026.11.17.765711
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- preprint